JP Morgan Chase’s Faeth Therapeutics FTH Stock Holding History
Bought
Maintained
Sold
Other funds holding FTH
SCM
ACA
BBA
FFM
LGM
RCM
VC
CP
BGI
JP Morgan Chase's FTH Position: Q2 2026 in Review
JP Morgan Chase increased its Faeth Therapeutics (FTH) stake by 25% in Q2 2026, buying an estimated $185 and bringing the position to 40 shares worth $929. The position accounts for ﹤0.01% of the portfolio, ranked #7338.
JP Morgan Chase first reported a position in FTH in Q1 2021 and has held it in 22 quarters since. The position peaked at $2.26M in Q1 2021. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.
- JP Morgan Chase held 40 shares of Faeth Therapeutics worth $929 as of Q2 2026.
- JP Morgan Chase bought 8 Faeth Therapeutics shares in Q2 2026, an estimated $185.
- Faeth Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7338 holding.
- JP Morgan Chase first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 22 quarters since.
- JP Morgan Chase's Faeth Therapeutics position peaked at $2.26M in Q1 2021.
- 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.